Compare Cytokinetics Inc (CYTK) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Banco Santander SA — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Banco Santander SA trades at $13.45 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 22.4× Cytokinetics Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Banco Santander SA for 55 Days on average.
| CYTK | SAN | |
|---|---|---|
Market Cap | $8.62B | $192.86B |
Volume | 2,594,626 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $87.26 | $15.05 |
52-Week Low | $54.76 | $9.65 |
Typical Hold Time | 19 Days | 55 Days |
Enterprise Value | $8.72B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Banco Santander (SAN) trades at $13.66, down 2.5% with bearish technical signals despite strong profitability metrics including 26.25% net margin and 16.07% ROE. The company completed its Webster Financial acquisition in August 2026, expanding U.S. presence while reporting record quarterly profits. Cash flow trends show recent operational challenges with negative $28.13B net cash flow in 2024, though revenue growth remains steady at $60.02B for 2025.
SAN presents a mixed outlook with strong fundamental performance offset by technical weakness. The acquisition-driven growth strategy and technological transformation support long-term value, but negative cash flows and high debt levels ($288.23B long-term debt) pose execution risks. Analyst consensus remains moderately bullish with 64% buy ratings, suggesting potential upside if operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
